|
1
|
Hung J, Kishimoto Y, Sugio K, et al:
Allele-specific chromosome 3p deletions occur at an early stage in
the pathogenesis of lung carcinoma. JAMA. 273:558–563. 1995.
View Article : Google Scholar
|
|
2
|
Wistuba II, Behrens C, Virmani AK, et al:
High resolution chromosome 3p allelotyping of human lung cancer and
preneoplastic/preinvasive bronchial epithelium reveals multiple,
discontinuous sites of 3p allele loss and three regions of frequent
breakpoints. Cancer Res. 60:1949–1960. 2000.
|
|
3
|
Zaborovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu GH, Salto-Tellez M, Ross JA, et al:
The tumor suppressor gene DLEC1 is frequently silenced by DNA
methylation in hepatocellular carcinoma and induces G1 arrest in
cell cycle. J Hepatol. 48:433–441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seng TJ, Currey N, Cooper WA, et al: DLEC1
and MLH1 promoter methylation are associated with poor prognosis in
non-small cell lung carcinoma. Br J Cancer. 99:375–382. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Daigo Y, Nishiwaki T, Kawasoe T, Tamari M,
Tsuchiya E and Nakamura Y: Molecular cloning of a candidate tumor
suppressor gene, DLC1, from chromosome 3p. 213. Cancer Res.
59:1966–1972. 1999.PubMed/NCBI
|
|
7
|
Kwong J, Chow LS, Wong WK, et al:
Epigenetic inactivation of deleted in lung and esophageal cancer 1
gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer.
46:171–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwong J, Lee JY, Wong KK, et al: Candidate
tumor-suppressor gene DLEC1 is frequently downregulated by promoter
hypermethylation and histone hypoacetylation in human epithelial
ovarian cancer. Neoplasia. 8:268–278. 2006. View Article : Google Scholar
|
|
9
|
Kang GH, Lee S, Cho NY, et al: DNA
methylation profiles of gastric carcinoma characterized by
quantitative DNA methylation analysis. Lab Invest. 88:161–170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Japan Lung Cancer Society. General Rule
for Clinical and Pathological Record of Lung Cancer. 5th edition.
Jpn Lung Cancer Soc. 5. pp. 1–177. 1999
|
|
11
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Endo K, Konishi A, Sasaki H, et al:
Epidermal growth factor receptor gene mutation in non-small cell
lung cancer using highly sensitive and fast TaqMan PCR assay. Lung
Cancer. 50:375–384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki H, Endo K, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LighyCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Smith IM, Mithani SK, Liu C, et al: Novel
integrative methods for gene discovery associated with head and
neck squamous cell carcinoma development. Arch Otolaryngol Head
Neck Surg. 135:487–495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakata S, Sugio K, Uramoto H, et al: The
methylation status and protein expression of CDH1, p16INK4A, and
fragile histidine triad in nonsmall cell lung carcinoma: epigenetic
silencing, clinical features, and prognostic significance. Cancer.
106:2190–2199. 2006. View Article : Google Scholar
|
|
17
|
Ying J, Poon FF, Yu J, et al: DLEC1 is a
functional 3p22.3 tumor suppressor silenced by promoter CpG
methylation in colon and gastric cancers. Br J Cancer. 100:663–669.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jarmalaite S, Kannio A, Anttila S, et al:
Aberrant p16 promoter methylation in smokers and former smokers
with non-small cell lung cancer. Int J Cancer. 106:913–918. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim DH, Nelson HH, Wiencke JK, et al:
p16(INK4a) and histology-specific methylation of CpG islands by
exposure to tobacco smoke in non-small cell lung cancer. Cancer
Res. 61:3419–3424. 2001.PubMed/NCBI
|
|
20
|
Rom WN, Jay JG, Lee TC, Jiang Y and
Tchou-Wong KM: Molecular and genetic aspects of lung cancer. Am J
Respir Crit Care Med. 161:1355–1367. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Swafford DS, Middleton SK, Palmisano WA,
et al: Frequent aberrant methylation of p16INK4a in primary rat
lung tumors. Mol Cell Biol. 17:1366–1374. 1997.PubMed/NCBI
|
|
22
|
Kim DS, Kim MJ, Lee JY, et al: Aberrant
methylation of E-cadherin and H-cadherin genes in non-small cell
lung cancer and its relation to clinicopathologic features. Cancer.
110:2785–2792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma BB, Sung F, Tao Q, et al: The
preclinical activity of the histone deacetylase inhibitor PXD101
(belinostat) in hepatocellular carcinoma cell lines. Invest New
Drugs. Jan 27–2009.(Epub ahead of print).
|
|
24
|
Takai N, Kawamata N, Gui D, Said JW,
Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: histone
deacetylase inhibitors exhibit antiproliferative activity and
potently induce apoptosis. Cancer. 15:2760–2770. 2004. View Article : Google Scholar
|
